Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-DAPT-HBR study of JAQBO (zastaprazan citrate) vs proton pump inhibitors for prevention of upper gastrointestinal events in high bleeding risk patients on dual antiplatelet therapy after PCI
KCT0011722Phase 4Recruiting
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zastaprazan in upper gastrointestinal bleeding (UGIB), Peptic ulcer disease (PUD), upper gastrointestinal disorders, sponsored by Jeil Pharmaceutical Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
zastaprazan
03
Conditions
upper gastrointestinal bleeding (UGIB)Peptic ulcer disease (PUD)upper gastrointestinal disorders
Beyond the preview
Go deeper on KCT0011722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011722.